Author | Bradley J. Monk, MD, FACOG, FACS | OncLive

Author | Bradley J. Monk, MD, FACOG, FACS

Articles

Dr. Monk on the FDA Approval of Maintenance Rucaparib in Ovarian Cancer

April 07, 2018

Video

Bradley J. Monk, MD, FACOG, FACS, professor and director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph's Hospital and Medical Center, Arizona Oncology, discusses the FDA approval of rucaparib (Rubraca) as a maintenance therapy for patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.

Dr. Monk Discusses Immunotherapy in Ovarian Cancer

December 12, 2017

Video

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for the treatment of patients with ovarian cancer.

How Reliable Is PD-L1 Expression as a Predictor of Immune Response?

November 09, 2017

Article

There is a great need—and opportunity—to improve ovarian cancer outcomes by understanding the immune milieu of ovarian cancers and harnessing the power of immunotherapy.

Dr. Monk on Immunotherapy for Gynecologic Cancer

April 19, 2017

Video

Bradley J. Monk, MD, FACOG, FACS, professor, director of the Division of Gynecologic Oncology at Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center in Phoenix, Arizona, discusses immunotherapy for patients with gynecologic cancer.

x